Rrraum / Shutterstock.com
1 June 2016Americas

Jazz buys Celator for $1.5bn

Jazz Pharmaceuticals, based in Ireland, will buy US company Celator Pharmaceuticals for $1.5 billion in cash.

The transaction will add Vyxeos (CPX-351), an investigational product in development as a treatment for acute myeloid leukaemia, to Jazz’s portfolio.

“Celator Pharmaceuticals is a strong strategic fit with Jazz Pharmaceuticals. Vyxeos will further diversify our product portfolio and is complementary to our clinical and commercial expertise in hematology/oncology,” said Bruce Cozadd, chairman and chief executive officer of Jazz.

The transaction is expected to close in the third quarter of 2016.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk